Clinical application and research progress of antibody drugs conjugation in breast cancer
10.12092/j.issn.1009-2501.2023.08.006
- Author:
Keyu CHEN
1
;
Keyu CHEN
2
;
Yuan HUANG
2
;
Xiaojia WANG
2
;
Yabing ZHENG
2
;
Yuan HUANG
3
;
Xiaojia WANG
3
;
Yabing ZHENG
3
Author Information
1. The Second Clinical Medical College of Zhejiang Chinese Medical University
2. Department of Breast Medical Oncology, The Cancer Hospital, the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital)
3. Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences
- Publication Type:Journal Article
- Keywords:
antibody drug conjugations;
breast cancer;
HER2;
HER3;
Trop-2
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2023;28(8):898-909
- CountryChina
- Language:Chinese
-
Abstract:
Antibody drug conjugations (ADCs) are a new class of drugs with both targeted specificity and high activity of chemotherapy drugs, which has gradually become a novel generation of therapeutic models with great clinical application prospects. In recent years, ADCs composed of monoclonal antibodies against different tumor cell surface antigens and small molecule potent cytotoxic drugs have shown superior therapeutic effects on recurrent / metastatic breast cancer. This article reviews the clinical application and research progress of ADCs with different molecular targets in the field of breast cancer.
